The cobas® EGFR Mutation Test v2 (cobas EGFR test [Roche Molecular Diagnostics GmbH, Mannheim, Germany]) is FDA-approved specifically for the detection of defined EGFR mutations in tissue or liquid biopsy (plasma) from patients with NSCLC [21]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.